532 Cardiomyopathies: from pathogenesis to treatment GLS (HR 1.4 95% CI 1.1-1.6, p<0.001) were significantly predictive of the primary endpoint, only LV GLS remained independently associated on multivariate analysis (HR 1.3, 95% CI 1.0-1.7, p=0.02). Those with LV GLS <-17.3% (median) were significantly more likely to be free of the primary endpoint at follow-up compared to those with LV GLS ≥-17.3% (log rank p=0.02). Conclusions: In ECS patients, LV GLS is reduced suggesting subclinical cardiac involvement despite absence of clinical or conventional echocardiographic evidence of cardiac disease. Furthermore, LV GLS is independently associated with the occurrence of adverse events and/or future development of accepted evidence for CS.
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Characterization of myocardial deformation in hypertrophic cardiomyopathy using speckle tracking: comparison with physiological hypertrophy Background: In young competitive athletes, the differential diagnosis between nonpathological changes in cardiac morphology associated with training (commonly referred to as "athlete's heart") and certain cardiac diseases with potential for sudden death as Hypertrophic Cardiomyopathy (HCM), is an important & not uncommon clinical problem.
Objective: This study was designed to characterize global & regional myocardial deformation using 2-dimensional strain & Strain Rate (SR) imaging in HCM & compare it to physiological hypertrophy in athletes.
Methods:
The study comprised 22 patients with HCM. 81% had asymmetric septal hypertrophy, 34 athletes with septal thickness >12 mm & 28 age matched healthy subjects as a control group. Apical four chamber view was displayed; speckle tracking was used to measure longitudinal peak systolic strain (εsys), peak systolic strain rate (SRsys), time to peak (ε) [TTP] , post systolic strain (εPSS) and intra-ventricular systolic delay (intra-V delay). Objective: To investigate whether alterations of myocardial strain and high sensitive cardiac Troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure. Methods: Sixty-five patients aged 52.46±13.58 years with newly-diagnosed large B-cell non-Hodgkin lymphoma treated with epirubicin were studied. Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after chemotherapy completion. After 4-6 months of chemotherapy, patients were studies using echocardiography. cTnT was detected with a highly sensitive assay. Longitudinal (LS), Circumferential (CS) and Radial Strain (RS) were calculated using two-dimensional speckle tracking echocardiography. Left Ventricular Ejection Fraction (LVEF) was analyzed by real-time 3D echocardiography. Cardiotoxicity was defined as a reduction of the Left Ventricular Ejection Fraction (LVEF) of ≥5% to <55% with symptoms of heart failure or an asymptomatic reduction of the LVEF of ≥10% to <55%. Results: LVEF remained stable and within normal limits in the whole course of chemotherapy, however decreased from 65.13±3.65% at baseline to 60.58±4.56% during follow-up (p=0.000). Twelve patients (18.46%) developed cardiotoxicity 4-6 months after treatment. Global LS (-18.56±1.69% vs -15.79±1.53%), CS (-20.88±2.67% vs -19.23±3.21%), RS (39.32±6.36% vs 34.79±6.15%) were markedly reduced and cTnT elevated from 0.0010±0.0020ng/ml to 0.0072±0.0035ng/ml (p all<0.01) at the completion of chemotherapy compared with baseline values. A >15.9% decrease in longitudinal strain (sensitivity: 86%, specificity: 75%) and a >0.004ng/ml elevation in cTnT levels (sensitivity: 79%, specificity: 64%) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity. Conclusions: Longitudinal strain combined with high sensitive cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy.
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Exercise capacity in patients with hypertrophic cardiomyopathy: non-invasive hemodynamic responses to exercise and association with clinical and imaging variables Background and aim: Hypertrophic cardiomyopathy (HCM) could be characterized by reduced exercise capacity. The intrinsic mechanisms affecting a reduced functional tolerance are not completely understood. The aim of the study was to determine the association between cardiopulmonary exercise test (CPET), non-invasively-determined hemodynamic variables, and clinical and echocardiographic variables and outcomes in patients with HCM. Methods: The study sample included 156 patients consecutively enrolled from 2007 to 2012 with a complete clinical assessment, including exercise echocardiography and CPX with impedence cardiography. Patients were followed for the composite outcome of cardiac-related death, heart transplant and functional deterioration leading to septal reduction (myectomy or alcholization). A Cox proportional hazard model was used to quantify determinants of the composite outcome. Results: Abnormalities in CPET parameters were commonly observed, with 39% (n=61) of our patients showing a reduced exercise tolerance (VO2 max < 80% of the predicted) and the 19% (n=30) characterized by an impaired ventilatory efficiency (VE/VCO2 > 34). The variables that were independently associated with peak VO2 (R2=0.65) were age (r=-0.32, p<0.001), male sex (r=0.31, p=0.001), E/E' (r=-0.24, p=0.014) and peak cardiac index (CI) (r=0.61, p<0.001). The variables most strongly associated (R2= 0.15) with VE/VCO2 slope were E/E' (r=0.23, p=0.021) and indexed left atrial volume (LAVi) (r=0.34, p=0.005). In our exploratory analysis, three variables were independently associated with the composite outcome (mean follow-up: 27±13 months): peak VO2 less than 80% of predicted (HR: 4.11 CI 1.46 to 11.59, p=0.008), VE/VCO2 slope > 34 (HR: 3.14 CI 1.26 to 7.87, p=0.014) and LAVi > 40 ml/m 2 (HR: 3.32 CI 1.08 to 10.16, p=0.036).
Conclusions:
In HCM peak CI is the main determinant of exercise capacity, but is not significantly related to ventilatory efficiency. Peak VO2, ventilatory efficiency and LAVi are major independent predictors of short/medium-term outcomes in HCM and could be helpful in the prognostic stratification of these patients. Purpose: Previously, in hypertrophic cardiomyopathy (HCM), only dense regional fibrosis could be identified by cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE) sequences. Recently, post-contrast T1 mapping has also enabled quantification of diffuse myocardial fibrosis. We sought to explore relationships between both patterns of myocardial fibrosis and several clinical parameters in a typical cohort of patients with HCM. Methods: We performed contrast-enhanced CMR on 123 patients (67% male, mean age 51±14 years) with documented HCM. Regional myocardial fibrosis was evaluated by LGE sequences, and diffuse fibrosis by post-contrast T1 mapping. Correlations between both patterns of fibrosis and patients' clinical characteristics, CMR-derived LV volumetric data and echocardiographic findings were investigated.
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Results:
LGE consistent with HCM was observed in 88% of patients with a mean quantity of 4.6±6.3% of total LV mass, and mean post-contrast myocardial T1 time was 495±81 ms. LGE extent correlated with LV ejection fraction (r = -0.48, p < 0.01) whereas T1 time did not. Conversely, T1 time correlated with E/e' (r = -0.46, p < 0.01) whereas LGE extent did not. Patients with LV outflow tract obstruction had less LGE (3.1±5.6% vs. 6.9±7.5%, p < 0.05), but similar T1 times. Patients with exertional dyspnoea had shorter T1 times (485±84 ms vs. 521±71 ms, p < 0.05), but similar LGE extent. No relationship was observed between LGE and post-contrast T1 time. Conclusions: In HCM, regional and diffuse patterns of myocardial fibrosis occur independently of each other and exhibit distinct clinical associations. Regional fibrosis is associated with reduced LV systolic function and the absence of LV outflow tract obstruction, whereas diffuse fibrosis is associated with higher LV filling pressures and the presence of exertional dyspnoea.
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Diffuse myocardial fibrosis in Alstrom syndrome: an early marker of disease progression . 16 (3) , P<0.05. There were no differences in LV ejection fraction or LA volumes. Increased septal myocardial ECV was inversely correlated with a MAPSE in patients with ALMS and hypertension (r = -0.74, p<0.05, r = -0.81, p<0.05).
Conclusion:
Patients with ALMS demonstrate increased septal myocardial fibrosis which correlates with reduced longitudinal contractility and increasing NT-BNP, before changes in conventional markers of LV structure and function. These data suggest that ECV and BNP may improve risk stratification for early introduction of pharmacological therapy in ALMS.
